Baseline characteristics were balanced between the apixaban and warfarin cohorts. The mean age was 64 years with a mean CCI score of 2.7
Warfarin cohort | Apixaban cohort | ||
---|---|---|---|
n (%) | n (%) | STD* | |
Sample size | 25,602 | 17,493 | |
Age, mean (SD) | 64.3 (14.3) | 64.5 (14.2) | 1.41 |
Gender | |||
Male | 10,504 (41.0) | 7,167 (41.0) | 0.12 |
Female | 15,098 (59.0) | 10,326 (59.0) | 0.12 |
Index VTE setting | |||
Inpatient | 16,530 (64.6) | 11,321 (64.7) | 0.32 |
Outpatient | 9,072 (35.4) | 6,172 (35.3) | 0.32 |
Index VTE event type | |||
DVT only | 12,214 (47.7) | 8,359 (47.8) | 0.16 |
PE with or without DVT | 13,388 (52.3) | 9,134 (52.2) | 0.16 |
Deyo-Charlson Comorbidity Index, Mean (SD) | 2.7 (2.6) | 2.7 (2.6) | 0.53 |